Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tillman Pearce

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Future Oncology (London, England)|November 4, 2021
The role of Globo H and SSEA-4 in the development and progression of cancer, and their potential as therapeutic targetsDarren S Sigal, David J Hermel, Pei Hsu, et al.
NPJ Digital Medicine|January 31, 2025
Convergence of evolving artificial intelligence and machine learning techniques in precision oncologyElena Fountzilas, Tillman Pearce, Mehmet A Baysal, et al.
Molecular Cancer Therapeutics|October 5, 2022
Demonstration of the Antitumor Activity of the iNKT Agonist ABX196, a Novel Enhancer of Cancer Immunotherapy, in Melanoma and Hepatocarcinoma Mouse ModelsDidier Scherrer, Noel Barrett, Luc Teyton, et al.
Investigational New Drugs|April 18, 2022
A phase II study of tarloxotinib (a hypoxia activated prodrug of a pan-erb tyrosine kinase inhibitor) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or skinLuke S McLean, Tessa A Morris, Ann Gramza, et al.
Veterinary Oncology (London, England)|August 6, 2025
Preliminary evaluation of the safety and feasibility of toll-like receptor ligand CB101 combined with hypofractionated radiation therapy in canine head and neck cancer: a pilot studyAudrey Ghanian, June DiBona, Lili Duda, et al.
Inflammatory Bowel Diseases|July 29, 2009
Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose studyWalter Reinisch, Williem de Villiers, László Bene, et al.
American Journal of Hematology|May 13, 2016
Phase I study of evofosfamide, an investigational hypoxia-activated prodrug, in patients with advanced leukemiaTalha Badar, Damian R Handisides, Juliana M Benito, et al.
Critical Care Medicine|May 25, 2012
Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosa: a randomized,double-blind, placebo-controlled trialBruno François, Charles-Edouard Luyt, Anthony Dugard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 25, 2019
OBI-3424, a Novel AKR1C3-Activated Prodrug, Exhibits Potent Efficacy against Preclinical Models of T-ALLKathryn Evans, JianXin Duan, Tara Pritchard, et al.
The Lancet. Oncology|June 28, 2017
Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trialWilliam D Tap, Zsuzsanna Papai, Brian A Van Tine, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Future Oncology (London, England)|November 4, 2021
The role of Globo H and SSEA-4 in the development and progression of cancer, and their potential as therapeutic targetsDarren S Sigal, David J Hermel, Pei Hsu, et al.
NPJ Digital Medicine|January 31, 2025
Convergence of evolving artificial intelligence and machine learning techniques in precision oncologyElena Fountzilas, Tillman Pearce, Mehmet A Baysal, et al.
Molecular Cancer Therapeutics|October 5, 2022
Demonstration of the Antitumor Activity of the iNKT Agonist ABX196, a Novel Enhancer of Cancer Immunotherapy, in Melanoma and Hepatocarcinoma Mouse ModelsDidier Scherrer, Noel Barrett, Luc Teyton, et al.
Investigational New Drugs|April 18, 2022
A phase II study of tarloxotinib (a hypoxia activated prodrug of a pan-erb tyrosine kinase inhibitor) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or skinLuke S McLean, Tessa A Morris, Ann Gramza, et al.
Veterinary Oncology (London, England)|August 6, 2025
Preliminary evaluation of the safety and feasibility of toll-like receptor ligand CB101 combined with hypofractionated radiation therapy in canine head and neck cancer: a pilot studyAudrey Ghanian, June DiBona, Lili Duda, et al.
Inflammatory Bowel Diseases|July 29, 2009
Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose studyWalter Reinisch, Williem de Villiers, László Bene, et al.
American Journal of Hematology|May 13, 2016
Phase I study of evofosfamide, an investigational hypoxia-activated prodrug, in patients with advanced leukemiaTalha Badar, Damian R Handisides, Juliana M Benito, et al.
Critical Care Medicine|May 25, 2012
Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosa: a randomized,double-blind, placebo-controlled trialBruno François, Charles-Edouard Luyt, Anthony Dugard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 25, 2019
OBI-3424, a Novel AKR1C3-Activated Prodrug, Exhibits Potent Efficacy against Preclinical Models of T-ALLKathryn Evans, JianXin Duan, Tara Pritchard, et al.
The Lancet. Oncology|June 28, 2017
Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trialWilliam D Tap, Zsuzsanna Papai, Brian A Van Tine, et al.
Pageof 1